Invitation to the presentation of Bactiguard’s interim report on May 9, 2019
Bactiguard Holding AB (publ) publishes the interim report for the first quarter on Thursday May 9, 2019 at 8:00 CET.
In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on May 9. CEO Christian Kinch and CFO Cecilia Edström will present the interim report and answer questions.
The report and a presentation for the conference call will be available at Bactiguard’s website www.bactiguard.com once the report has been released.
To participate in the conference call, please dial +46 8 505 583 56
For further information, please contact:
Cecilia Edström, CFO, mobile: +46 722 262 328
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 70 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives on www.bactiguard.com